Daily Stock Analysis, AMRN, Amarin Corporation PLC, priceseries

Amarin Corporation PLC. Daily Stock Analysis
Stock Information
Open
18.39
Close
18.49
High
18.90
Low
18.05
Previous Close
18.39
Daily Price Gain
0.10
YTD High
23.25
YTD High Date
Mar 5, 2019
YTD Low
12.44
YTD Low Date
Jan 3, 2019
YTD Price Change
5.48
YTD Gain
42.12%
52 Week High
23.34
52 Week High Date
Nov 6, 2018
52 Week Low
2.35
52 Week Low Date
Jul 31, 2018
52 Week Price Change
15.81
52 Week Gain
589.93%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 2. 2017
2.96
Feb 22. 2017
3.40
13 Trading Days
14.90%
Link
LONG
Jun 19. 2017
3.00
Jul 13. 2017
4.00
17 Trading Days
33.38%
Link
LONG
Sep 22. 2017
3.29
Oct 10. 2017
3.47
12 Trading Days
5.53%
Link
LONG
Dec 15. 2017
3.39
Jan 16. 2018
4.16
19 Trading Days
22.69%
Link
LONG
Sep 24. 2018
12.40
Oct 30. 2018
20.02
26 Trading Days
61.42%
Link
LONG
Jan 9. 2019
15.03
Jan 28. 2019
16.49
12 Trading Days
9.73%
Link
LONG
Feb 21. 2019
17.43
Mar 13. 2019
20.62
14 Trading Days
18.31%
Link
Company Information
Stock Symbol
AMRN
Exchange
NasdaqGM
Company URL
http://www.amarincorp.com
Company Phone
ELY CAMBRIDGESHIRE X0 FK7 9JQ
CEO
John F. Thero
Headquarters
-
Business Address
-
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Other
CIK
0001120246
About

Amarin Corp. Plc is a biopharmaceutical company, which engages in the commercialization and development of therapeutics for cardiovascular health. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Description

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. Amarin Corporation plc sells its product principally to wholesalers and specialty pharmacy providers. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.